STAT

FEBRUARY 5, 2024

The prediction is dire: Cancer cases around the world are expected to surge 77% by 2050, a new report from the World Health Organization estimates. That attention-grabbing statistic, based on an analysis of 185 countries, cites a growing, aging population and factors including tobacco, alcohol, obesity, and pollution. Perhaps the most damning part of the report reveals the disparities determined by income.

360

360

ALiEM - Pharm Pearls

FEBRUARY 5, 2024

Welcome to the AIR Toxicology Module! After carefully reviewing all relevant posts in the past 12 months from the top 50 sites of the Digital Impact Factor [1], the ALiEM AIR Team is proud to present the highest quality online content related to related to toxicology in the Emergency Department. 8 blog posts met our standard of online excellence and were approved for residency training by the AIR Series Board.

212

212

STAT

FEBRUARY 5, 2024

Katie Keim was diagnosed with type 1 diabetes in 1967 when she was eight, well before the era of insulin pumps or even reliable home testing. The condition started eating away at her vision 20 years later. By the time she was 36, her sight was completely gone.  Keim had lived an independent life as a child despite her illness. Her summers were spent exploring oceans with her family, not at diabetic summer camps.

Diabetes 352

Diabetes 352

Safe Biologics

FEBRUARY 5, 2024

On January 31st, ASBM released a fact sheet describing a variety of proposed policy changes at the state and federal level which would weaken the interchangeable biosimilar standard, or circumvent the patient protections it provides. These include new bills and regulations at the federal level, as well as state legislation and proposals which threaten to undermine the hard-won gains of the patient and physician communities to ensure that only interchangeable biosimilars are substituted without p

Biosimilars 130

Biosimilars 130

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

FEBRUARY 5, 2024

After a months-long fight with Texas Medicaid over coverage of a gene therapy, Afghan refugees now have a chance to save their infant son. After initially balking , Texas officials have agreed to pay for the costly treatment, the boy’s family and his doctor told STAT. At the end of last week, N. Pashai’s cell phone rang. It was from a Minnesota area code.

Hospitals 349

Hospitals 349

PharmaVoice

FEBRUARY 5, 2024

The biotech’s bone- and muscle-building treatments could someday help humans reach other planets.

163

163

The Pharmacist

FEBRUARY 5, 2024

The last 12 months have seen a marked increase in patients declining prescription medication because of cost, according to new research. The findings have subsequently sparked fresh calls for prescription charges to be reviewed or abolished. A survey of 1,357 pharmacists in England found that 97% had encountered patients foregoing some of the medicines on […] The post Pharmacists report rise in patients unable to collect prescriptions due to cost appeared first on The Pharmacist.

117

117

STAT

FEBRUARY 5, 2024

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.   Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally.

Diabetes 346

Diabetes Pharmaceutical Companies Pharmaceutical Companies 346

The Pharmacist

FEBRUARY 5, 2024

Pharmacies currently providing the Covid-19 vaccine are being asked by NHS England (NHSE) to extend their service provision contracts until 31 August 2024. The extension covers a potential spring booster programme, with the Joint Committee on Vaccination and Immunisation (JCVI) set to publish their guidance soon. While the fee for the extension period remains at […] The post Covid-19 vaccine contract extensions to carry added spring payment appeared first on The Pharmacist.

Vaccines 116

Vaccines 116

STAT

FEBRUARY 5, 2024

At the end of each chapter in “Rebel Health: A Field Guide to the Patient-Led Revolution in Medical Care,” there’s a box. It summarizes the chapter, distilling what a reader just encountered into easy-to-digest bullet points. The author, Susannah Fox, admits she stole that idea from “The Long Covid Survival Guide,” which was written by patients for patients.

Drug Development 346

Drug Development 346

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

PharmaVoice

FEBRUARY 5, 2024

Patent thickets are the latest target in lawmakers' bid to lower drug prices.

Drug Pricing 130

Drug Pricing 130

STAT

FEBRUARY 5, 2024

Starting this year, private Medicare plans have to cover their members’ hospitalizations at the higher inpatient rate if their doctors predict they’ll have to stay beyond two midnights. It’s the same rule — appropriately called the two-midnight rule — that traditional Medicare has followed for a decade. After it came out that Medicare Advantage plans were routinely denying coverage for necessary services , the federal government decided they ought to be held to

Hospitals 290

Hospitals Inpatient 290

pharmaphorum

FEBRUARY 5, 2024

Data science in healthcare is transforming the industry, from drug discovery to patient care. Learn about the role of data, artificial intelligence (AI), and the impact of initiatives like the NHS Datastore in revolutionising healthcare outcomes.

115

115

STAT

FEBRUARY 5, 2024

Sixteen billion dollars is a lot of money. But Monday’s announcement that the parent company of Novo Nordisk, the maker of the weight loss drug Wegovy, plans to buy Catalent , a company to which drugmakers outsource manufacturing, is probably even more important than it seems. The deal, done in part so that Novo can rapidly ramp up its ability to manufacture Wegovy, is a massive statement of optimism about the sales potential of that medication and weight loss drugs like it, known as GLP-

Vaccines 274

Vaccines 274

BioPharma Dive

FEBRUARY 5, 2024

The pharma disclosed positive results from two studies testing its antibody drug nipocalimab in generalized myasthenia gravis or Sjögren's disease.

122

122

STAT

FEBRUARY 5, 2024

Devoted Health has been one of the most prominent health insurance and provider startups of the past decade — founded and overseen by several alumni of former President Barack Obama’s administration. But it has not turned a profit after five years of selling Medicare Advantage plans to older adults, according to a STAT analysis of Devoted’s financial filings.

Health Insurance Companies 263

Health Insurance Companies 263

The Pharmacist

FEBRUARY 5, 2024

Illegally traded medicines with a street value of more than £30m were seized by the Medicines and Healthcare products Regulatory Agency (MHRA) in 2023. The seizures were made as part of an international initiative called Operation Pangea and accounted for more than 15.5 million doses. Among the illegally traded medicines were prescription-only anti-anxiety medication, opioids […] The post More than 15.5 million doses of illegal medicines seized in 2023 appeared first on The Pharmacist.

109

109

STAT

FEBRUARY 5, 2024

Novartis said late Monday it has agreed to buy German biotech MorphoSys and its pipeline of cancer drugs for 2.7 billion euros, or $2.9 billion. The Swiss drugmaker will pay 68 euros, or around $73, per share, nearly twice Morphosys’s average trading price over the last month. At the center of the deal is pelabresib, a blood cancer pill that in November posted mixed results in a Phase 3 trial.

224

224

Pharma Times

FEBRUARY 5, 2024

The aggressive brain cancer is responsible for over 3,000 cases in the UK every year

149

149

STAT

FEBRUARY 5, 2024

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of phone calls, online meetings, and deadlines has predictably returned. But you knew this would happen. After all, the world keeps spinning, at least for now. So time to give it a nudge in a better direction with a cup of delicious stimulation.

Diabetes 216

Diabetes 216

BioPharma Dive

FEBRUARY 5, 2024

In a related deal, Novo Holdings subsidiary Novo Nordisk will buy three major Catalent factories for $11 billion as it works to keep pace with demand for its obesity and diabetes medicines.

Diabetes 109

Diabetes 109

STAT

FEBRUARY 5, 2024

More than half of the injector-pen patents for several widely used diabetes treatments — including Ozempic and Mounjaro — do not mention several important characteristics that should otherwise prevent them from being listed in a key federal registry, according to a new analysis. As a result, the researchers contend the patents may be unfairly used to preclude competition from companies that may want to market lower-cost generic products.

Diabetes 223

Diabetes 223

pharmaphorum

FEBRUARY 5, 2024

A bladder cancer study prompts Astellas to lift peak sales prediction for Padcev, although its menopause therapy Veozah isn’t ramping up as hoped.

110

110

STAT

FEBRUARY 5, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Today, we talk about two players that want to join the obesity market with updates to the GLP-1 class: Amgen and Regeneron. Also, a draft bill in Congress would restrict U.S. involvement with Chinese biotechs.

Drug Pricing 201

Drug Pricing Drug Development 201

pharmaphorum

FEBRUARY 5, 2024

Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in the last quarter of 2023.

99

99

Express Pharma

FEBRUARY 5, 2024

SGD Pharma has launched its new range of Type I injectable vials in tubular glass with the added external low-friction coating developed by Corning thanks to an exclusive co-development partnership. A company statement informed, “SGD Pharma’s new Velocity Vial offering reduces the frictional resistance created by glass-to-glass and glass-to-metal contact, helping pharma filing lines to prevent potential disruptions to the flow of vials, which can include tip-overs, jams and glass breakages.

Packaging 101

Packaging 101

Outsourcing Pharma

FEBRUARY 5, 2024

No new treatments to combat the major public health issue of alcohol use disorder (AUD), have been brought to market for ten years - and with half of heavy drinkers refusing the abstinence route, new drug could be the answer.

97

97

Express Pharma

FEBRUARY 5, 2024

Merck has recently agreed to acquire cancer drug developer Harpoon Therapeutics for about $680 million. The deal includes promising compounds undergoing Phase II trials for malignancies and access to the Tri-specific T cell Activating Construct (TriTAC) platform, positioning the US-based pharma giant for significant advancements in therapeutic innovation.

Compounding 97

Compounding Drug Development 97

pharmaphorum

FEBRUARY 5, 2024

4D Molecular Therapeutics' 4D-150 gene therapy for wet AMD has shown efficacy and a reduced need for eye injections with current therapy Eylea in a phase 2 trial.

97

97

European Pharmaceutical Review

FEBRUARY 5, 2024

Novo Nordisk is set to acquire three fill-finish manufacturing sites from Novo Holdings A/S (Novo Holdings) for $11 billion. This agreement is part of a transaction in which Novo Holdings agreed to acquire the contract development and manufacturing organisation (CDMO) Catalent. The three manufacturing sites in Anagni in Italy, Brussels in Belgium and in Bloomington, Indiana in the US, specialise in the sterile filling of drugs.

Diabetes 94

Diabetes 94

pharmaphorum

FEBRUARY 5, 2024

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes and obesity drugs. The deal includes $11 billion upfront to buy the fill-finish sites that Novo Nordisk said will enable “an expansion of the manufacturing capacity at scale and speed while providing future optionality and flexibility for Novo Nordisk’s existing supply network.

Diabetes 93

Diabetes 93

Express Pharma

FEBRUARY 5, 2024

The Consensus Guidelines for the Management of Head and Neck Cancer (HNC), developed under the aegis of Oral Cancer Task Force (OCTF) supported by the Biocon Foundation, has been recognised amongst the 13 worldwide clinical practice guidelines by Cancers, an international, peer-reviewed, open access journal of oncology. The OCTF’s consensus guidelines was included in journal Cancers as part of a scoping review that identified and compared the worldwide clinical practice guidelines for treating o

92

92

pharmaphorum

FEBRUARY 5, 2024

The 38th PM Society Awards will take place on Friday 15th March in London, with Twist Health as the headline sponsor. It is the longest running and largest awards event in the pharma marketing and healthcare agency calendar. To view all the finalist agencies and clients, please visit the PM Society’s website.

90

90

The Pharmacist

FEBRUARY 5, 2024

Allowing emergency hormonal contraception (EHC) to be sold in non-pharmacy settings would be ‘to the detriment’ of patients, former Royal Pharmaceutical Society chair for England Thorrun Govind has told The Pharmacist. This follows calls from the Faculty of Sexual and Reproductive Healthcare (FSRH) earlier this month to reclassify oral emergency contraception from its current Pharmacy […] The post General sale morning-after pill could be ‘detrimental’ to patients appeared first on The Phar

89

89

Outsourcing Pharma

FEBRUARY 5, 2024

Life sciences technology company ArisGlobal, has announced the formal charter for the new generative AI Council, which will sit for the first time this month in a bid to advance life sciences innovation.

86

86